hepat
e
viru
hev
infect
caus
hepat
human
worldwid
associ
mortal
rate
pregnant
women
recent
persist
chronic
hev
infect
recogn
seriou
clinic
problem
especi
immunocompromis
individu
date
fdaapprov
hevspecif
antivir
drug
studi
evalu
antisens
peptideconjug
morpholino
oligom
ppmo
design
hev
genom
sequenc
potenti
hevspecif
antivir
compound
two
geneticallydistinct
strain
human
hev
genotyp
genotyp
isol
patient
acut
chronic
hepat
respect
use
evalu
inhibit
viral
replic
ppmo
liver
cell
antihev
ppmo
produc
signific
reduct
level
hev
rna
capsid
protein
indic
effect
inhibit
hev
replic
ppmo
target
highli
conserv
sequenc
start
site
region
also
effect
genotyp
strain
stablyinfect
liver
cell
antivir
activ
observ
specif
doserespons
potent
suggest
explor
ppmo
potenti
hevspecif
antivir
agent
warrant
hepevirida
emerson
et
al
hev
etiolog
agent
acut
hepat
human
endem
variou
tropic
subtrop
region
world
pregnant
women
infect
hev
genotyp
lead
fulmin
hepat
mortal
rate
jameel
kumar
et
al
hepat
e
recogn
zoonot
diseas
strain
hev
pig
chicken
mongoos
rabbit
rat
ferret
bat
fish
deer
genet
character
haqshena
et
al
li
et
al
meng
meng
et
al
past
sever
year
chronic
persist
symptomat
hev
infect
report
increas
number
immunocompromis
individu
includ
organ
transplant
recipi
leukemia
lymphoma
hivaid
patient
industri
countri
kamar
et
al
hev
genom
approxim
kb
length
consist
three
open
read
frame
orf
tam
et
al
encod
put
nonstructur
protein
involv
hev
replic
encod
capsid
protein
major
structur
protein
hev
virion
encod
multifunct
phosphoprotein
essenti
establish
hev
infect
macaqu
pig
graff
et
al
huang
et
al
hev
strain
highli
divers
sequenc
strain
infect
human
classifi
four
major
genotyp
genu
orthohepeviru
lu
et
al
smith
et
al
hev
genotyp
restrict
human
known
anim
reservoir
wherea
genotyp
infect
sever
anim
speci
addit
human
known
zoonot
ahmad
et
al
meng
although
two
decad
sinc
sequenc
fulllength
hev
genom
first
publish
tam
et
al
yet
fdaapprov
hevspecif
drug
offlabel
use
ribavirin
pegyl
interferon
treatment
acut
chronic
hepat
e
patient
report
gerolami
et
al
kamar
et
al
mallet
et
al
wedemey
et
al
side
effect
efficaci
concern
respect
option
kamar
et
al
pischk
et
al
ribavirin
belong
fda
pregnanc
risk
categori
x
recommend
use
pregnant
women
interferon
use
transplant
patient
thu
press
need
develop
hevspecif
antivir
therapeut
agent
especi
treat
sever
infect
pregnant
women
chronic
infect
immunocompromis
patient
studi
phosphorodiamid
morpholino
oligom
pmo
test
abil
inhibit
hev
replic
liver
cell
pmo
nucleaseresist
singlestrand
dna
analog
contain
backbon
morpholin
ring
phosphorodiamid
linkag
summerton
pmo
bind
mrna
watsoncrick
base
pair
interfer
translat
steric
blockad
augtransl
start
site
region
conjug
pmo
argininerich
cell
penetr
peptid
yield
peptideconjug
pmo
ppmo
facilit
deliveri
cell
abe
et
al
summerton
ppmo
water
solubl
enter
cell
readili
studi
demonstr
sever
antihev
ppmo
display
potent
inhibit
hev
genotyp
replic
notabl
ppmo
target
start
site
region
hev
also
effect
inhibit
replic
genotyp
strain
liver
cell
base
previou
studi
target
viral
rna
ppmo
stein
ppmo
studi
design
target
genom
sequenc
hev
strain
genbank
access
ppmo
complementari
sequenc
region
genom
subgenom
rna
respect
fig
tabl
complementari
sequenc
termin
region
utr
revers
complement
intend
interfer
synthesi
positivesens
genom
rna
nonsensesequ
ppmo
zhang
et
al
littl
agreement
hev
human
mrna
sequenc
use
neg
control
ppmo
fluorescein
conjug
use
ppmo
uptak
assay
ppmo
synthes
argininerich
cellpenetr
peptid
conjug
avi
biopharma
inc
corval
previous
describ
abe
et
al
ppmo
target
sequenc
clone
upstream
luciferas
gene
report
vector
pcineolucr
previous
describ
zhang
et
al
briefli
oligom
length
contain
target
sequenc
ppmo
clone
upstream
luciferas
code
sequenc
pcineolucr
vector
vitro
transcript
translat
reaction
carri
previous
describ
zhang
et
al
luminesc
signal
measur
multilabel
counter
perkinelm
life
analyt
scienc
wellesley
cell
subclon
hepatoma
cell
graff
et
al
hepatoma
cell
atcc
maintain
dmem
medium
supplement
fetal
bovin
serum
ppmo
uptak
assay
perform
uninfect
cell
approxim
cell
seed
per
well
plate
produc
confluent
monolay
h
ppmo
ad
cell
supernat
final
concentr
cell
incub
h
medium
remov
cell
rins
pb
observ
fluoresc
microscopi
assess
ppmo
uptak
effici
transfect
cell
hev
rna
vitro
transcrib
infecti
cdna
clone
hev
strain
contain
luciferas
report
perform
use
dmriec
reagent
invitrogen
grand
island
ny
previous
describ
nan
et
al
nan
et
al
ppmo
treatment
cell
plate
cell
cultur
supernat
discard
hour
rna
transfect
cell
rins
twice
optimem
ppmo
suspend
ml
optimem
ad
cell
monolay
four
hour
ppmo
treatment
ppmo
solut
remov
ml
dmem
fb
ad
well
cell
incub
day
prior
analysi
viral
protein
rna
luciferas
signal
luciferas
activ
determin
use
brightglo
luciferas
assay
system
promega
madison
wi
hev
genotyp
strain
use
infect
cell
multipl
infect
moi
shukla
et
al
replic
caus
cytopath
effect
infect
cell
passag
five
time
produc
stabli
infect
cell
immunofluoresc
assay
ifa
chimpanze
antihev
antibodi
gift
suzann
emerson
nation
institut
health
conduct
confirm
viru
replic
subsequ
cell
seed
plate
ppmo
ad
cell
fresh
medium
everi
two
day
day
treatment
total
cell
maintain
harvest
analysi
one
day
final
ppmo
treatment
viabil
cell
ppmo
treatment
determin
luminesc
cell
viabil
assay
promega
cell
treat
ppmo
describ
seven
day
viabil
measur
accord
manufactur
instruct
ifa
confoc
fluoresc
microscopi
carri
report
previous
chimpanze
antibodi
hev
capsid
protein
nan
et
al
cell
lyse
laemmli
sampl
buffer
total
protein
subject
sodium
dodecylsulfatepolyacrylamid
gel
electrophoresi
sdspage
western
blot
describ
previous
patel
et
al
zhang
et
al
antihev
monoclon
antibodi
clone
emd
millipor
billerica
use
dilut
riddel
et
al
quantiti
one
program
version
chemidoc
xr
imag
system
biorad
laboratori
hercul
ca
use
digit
signal
acquisit
densitometri
analys
also
detect
protein
load
control
rna
isol
revers
transcript
realtim
pcr
perform
previous
describ
nan
et
al
nan
et
al
detect
hevspecif
rna
hev
specif
revers
primer
cagaatccacgcagacctta
use
revers
transcript
primer
tgagtttgattccacccaga
use
realtim
pcr
sybr
greenbas
cdna
absolut
quantif
hev
rna
plasmid
serv
templat
establish
standard
curv
student
ttest
use
assess
statist
signific
differ
level
luciferas
signal
hev
rna
copi
group
cell
receiv
indic
ppmo
treatment
compar
treatment
two
tail
pvalu
less
consid
signific
valid
bind
ppmo
respect
target
sequenc
ppmo
test
rna
contain
ppmo
target
region
upstream
frame
luciferas
code
sequenc
ppmo
ad
variou
concentr
cellfre
translat
reaction
contain
vitro
transcrib
rna
report
plasmid
compar
hevtarget
ppmo
reduc
luciferas
signal
significantli
fig
ppmo
produc
reduct
nm
fig
similarli
ppmo
reduc
luciferas
express
around
nm
fig
ppmo
behav
dosedepend
manner
produc
potent
inhibit
next
conduct
ppmo
uptak
assay
uninfect
cell
ppmo
highli
effici
uptak
observ
indic
presenc
green
fluoresc
signal
present
cell
fig
establish
ppmo
enter
cell
effect
next
test
whether
ppmo
design
abl
inhibit
hev
replic
cell
transfect
fulllength
rna
treat
ppmo
dose
chosen
base
previou
studi
zhang
et
al
zhang
et
al
ppmo
produc
mark
reduct
capsid
protein
express
indic
inhibit
hev
replic
minim
effect
fig
result
indic
four
hevtarget
ppmo
gener
specif
inhibit
hev
replic
also
test
whether
ppmo
produc
cytotox
cell
impact
cell
viabil
could
produc
nonspecif
inhibit
viral
replic
uninfect
cell
treat
ppmo
condit
antivir
assay
impact
cell
viabil
observ
data
shown
next
hev
replicon
system
contain
luciferas
report
use
verifi
antivir
effect
select
ppmo
replicon
insert
luciferas
code
sequenc
hev
region
disrupt
express
provid
quantit
mean
measur
translat
subgenom
viral
rna
graff
et
al
ppmo
includ
test
due
presum
disrupt
bind
site
luciferas
insert
cell
transient
transfect
treat
ppmo
luciferas
yield
cell
treat
reduc
respect
compar
mocktreat
cell
fig
evalu
show
ppmo
gener
dosedepend
reduct
luciferas
express
fig
luciferas
express
cell
treat
reduc
respect
compar
mocktreat
control
ppmo
reduc
luciferas
express
use
respect
ppmo
reduc
luciferas
express
respect
three
ppmo
test
two
cellbas
system
produc
potent
inhibit
hev
replic
addit
sequenc
analysi
indic
target
sequenc
conserv
thu
select
evalu
cell
inhibit
viru
replic
evalu
western
blot
detect
hev
capsid
protein
cell
receiv
treatment
rel
capsid
protein
respect
cell
treat
indic
densitometri
analysi
western
blot
fig
next
test
ppmo
treatment
reduc
level
hev
rna
product
cell
transfect
rna
base
result
treat
hev
rna
present
supernat
cell
cultur
detect
rtqpcr
seven
day
post
transfect
treatment
led
signific
reduct
hev
rna
copi
less
copi
per
ml
fig
result
consist
capsid
protein
detect
luciferas
report
assay
describ
genotyp
hev
strain
success
adapt
propag
cell
shukla
et
al
sinc
replic
caus
cytopath
effect
establish
cell
stabli
infect
viru
multipl
round
passag
activ
replic
hev
cell
confirm
ifa
western
blot
fig
b
sequenc
align
reveal
target
sequenc
ppmo
genotyp
genotyp
conserv
nt
mismatch
strain
target
site
therefor
test
ppmo
kernowinfect
cell
found
reduc
capsid
protein
level
untreat
cell
fig
thorough
evalu
show
dosedepend
inhibit
protein
express
fig
taken
togeth
data
experi
use
two
hev
genotyp
three
differ
cellbas
system
show
ppmo
effect
inhibitor
hev
replic
result
demonstr
ppmo
target
hev
rna
inhibit
hev
replic
effect
inhibit
hev
replic
cell
demonstr
reduct
viral
rna
capsid
protein
level
ppmo
target
initi
region
effect
inhibit
replic
genotyp
strain
well
establish
infect
genotyp
strain
target
site
perfectli
conserv
hev
genotyp
one
base
varianc
type
data
shown
conserv
natur
target
site
overal
efficaci
ppmo
studi
suggest
may
hevspecif
inhibitor
antivir
activ
across
multipl
hev
genotyp
ppmo
abl
inhibit
replic
dosedepend
manner
target
site
termin
region
end
hev
genom
plusstrand
replicativeintermedi
minusstrand
respect
hev
rnadepend
rna
polymeras
rdrp
presum
associ
rna
synthesi
specul
two
ppmo
may
obstruct
access
rdrp
respect
rna
therebi
interf
viral
rna
synthesi
antisens
pmo
current
clinic
trial
includ
treatment
duchenn
muscular
dystrophi
human
anthoni
et
al
mendel
et
al
ppmo
also
use
clinic
trial
albeit
exvivo
model
moulton
ppmo
document
effect
numer
type
viral
infect
liver
experiment
anim
model
importantli
upon
system
administr
ppmo
distribut
liver
tissu
remain
pharmacolog
viabl
effect
reduc
viral
titer
amantana
et
al
burrer
et
al
paessler
et
al
qualiti
along
efficaci
hev
replic
cultur
cell
observ
studi
suggest
ppmo
consid
develop
inhibitor
hev
infect
evalu
develop
antihev
ppmo
requir
vivo
investig
pig
model
infect
genotyp
hev
appear
suitabl
studi
meng
et
al
summari
result
indic
ppmo
effect
antivir
compound
hev
infect
ppmo
potent
activ
strain
hev
two
differ
genotyp
includ
establish
infect
cell
genotyp
strain
result
suggest
promis
candid
develop
hevspecif
antivir
compound
peptideconjug
morpholino
oligom
ppmo
design
hepat
e
viru
hev
four
ppmo
effect
inhibit
replic
genotyp
hev
strain
ppmo
also
inhibit
hev
genotyp
hev
strain
stabli
infect
cell
may
good
candid
explor
hevspecif
antivir
compound
ppmo
uptak
assay
cell
fluoresceinconjug
without
fluorescein
conjug
ad
cell
incub
h
fluoresc
microscopi
green
fluoresc
indic
uptak
ppmo
bright
field
illumin
shown
next
fluoresc
imag
b
immunofluoresc
assay
cell
infect
hev
cell
transfect
rna
transcrib
treat
indic
ppmo
hour
later
fix
ifa
day
posttransfect
panel
left
imag
show
ifa
use
hevspecif
antibodi
right
imag
show
field
cell
nuclei
stain
dapi
green
scale
bar
lower
right
corner
repres
luciferas
assay
cell
transfect
rna
hev
replicon
cell
transfect
viral
rna
treat
ppmo
h
later
harvest
luciferas
assay
day
posttransfect
rel
percentag
luciferas
activ
shown
comparison
mocktreat
cell
error
bar
repres
standard
error
among
three
repeat
experi
indic
signific
differ
mocktreat
cell
p
b
dosedepend
inhibit
hev
replic
ppmo
use
experiment
scheme
c
treatment
cell
ppmo
inhibit
hev
capsid
protein
product
dosedepend
manner
cell
transfect
hev
rna
treat
ppmo
h
later
harvest
day
later
western
blot
repres
blot
three
independ
experi
shown
hev
rna
level
present
supernat
cell
treat
ppmo
cell
transfect
rna
treat
ppmo
h
later
cell
cultur
supernat
harvest
day
posttransfect
rna
detect
rtqpcr
result
show
averag
four
repeat
treatment
